Xcellent idea

LOCAL medical devices company Xcell Diagnostics has formalised its acquisition of local business InfaMed and the patented Funhaler.

InfaMed has developed a small volume spacer device for children who suffer from asthma, named the Funhaler.

The fully-approved acquisition of shares in InfaMed, announced at this week’s general meeting, makes it a wholly owned subsidiary of Xcell, according to managing director Barry Fehlberg.

Clinical trials of the Funhaler are currently under way at the University of Western Australia with the support of a $450,000 Federal Government grant.

Xcell is also involved in research on a skin cancer analysis, which involves funding skin cancer research utilising diffuse reflectance spectroscopy at the UWA.